![Orgad Laub](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Orgad Laub
Chief Executive Officer at Sealantium Medical Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Paul Gregor | M | - |
Rimonyx Pharmaceuticals Ltd.
![]() Rimonyx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel | 23 years |
Regina Zhuk | M | - |
Rimonyx Pharmaceuticals Ltd.
![]() Rimonyx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel | - |
Miki Ben-Dor | M | - |
Rimonyx Pharmaceuticals Ltd.
![]() Rimonyx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel | - |
Alan Lewis | M | - |
Rimonyx Pharmaceuticals Ltd.
![]() Rimonyx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel | - |
Stanley Hirsch | M | - |
Rimonyx Pharmaceuticals Ltd.
![]() Rimonyx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel | - |
Yonatan Naveh | M | - |
Sealantium Medical Ltd.
![]() Sealantium Medical Ltd. Medical SpecialtiesHealth Technology Sealantium Medical Ltd. develops a biodegradable bandage for the control of hemorrhage (bleeding), used in first aid, field trauma care, and surgery. The company was founded by Orgad Laub in 2011 and is headquartered in Netanya, Israel. | 5 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Israel | 6 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Orgad Laub
- Personal Network